The role of nuclear medicine in the diagnosis of cancer of unknown origin
Research output: Contribution to journal › Journal article › Research › peer-review
Cancer of unknown origin (CUO) is defined by the absence of any primary tumour in biopsy-proved metastatic cancer. CUO accounts for a 5-10% of all malignancies. These tumors have a specific biology with clinical characteristics of rapid progression and atypical metastases. Diagnostic evaluation is directed at the identification of treatable subset. Accurate diagnostic workup is crucial because both prognosis and survival rates depend mainly on detection of the primary tumor site. Although these patients undergo extensive imaging procedures, nuclear medicine techniques are under-utilized despite their ability of providing molecular information. Positron emission tomography has an emerging role in this clinical challenge along with other nuclear medicine methods including, bone scan, thyroid scintigraphy.
|Journal||American Journal of Nuclear Medicine and Molecular Imaging|
|Number of pages||10|
|Publication status||Published - Jun 2004|
- Biomarkers, Tumor, Bone Neoplasms, Bone and Bones, Fluorodeoxyglucose F18, Humans, Lymphatic Metastasis, Neoplasms, Unknown Primary, Prognosis, Radiopharmaceuticals, Tomography, Emission-Computed, Tomography, Emission-Computed, Single-Photon, Journal Article, Review